ABSTRACT
Abstract Objective To verify how the combined administration of alendronate (ALN) and vitamin D3 (VD) acts on the bone microarchitecture in rats with glucocorticoid-induced osteoporosis. Methods The experiment used 32 90-day-old female Wistar rats weighing between 300 and 400g. The induction of osteoporosis consisted of intramuscular administration of dexamethasone at a dose of 7.5 mg/kg of body weight once a week for 5 weeks, except for the animals in the control group. The animals were separated into the following groups: G1 (control group without osteoporosis), G2 (control group with osteoporosis without treatment), G3 (group with osteoporosis treated with ALN 0.2 mg/kg), G4 (group with osteoporosis treated with VD 10,000UI/500μL), and G5 (group with osteoporosis treated with ALN þ VD). The right femurs of the rats were fixed in 10% buffered formaldehyde, decalcified, and processed for inclusion in paraffin. Histological sections were stained with hematoxylin-eosin for histomorphometric analysis. Cortical thickness and medullary cavity were measured in cross-sections. Results There was a statistical difference (p< 0.05) between groups G3 and G5 compared with the positive control group (G2), both related to the measurement of cortical thickness and to the total diameter of the bone. In the evaluation of the spinal area, only the G3 group has shown to be statistically different from the G2 group. Conclusion Concomitant treatment with daily ALN and weekly VD is effective in preventing glucocorticoid-induced bone loss. However, there was no difference between the therapy tested and treatment with ALN alone.
Resumo Objetivo Verificar como a administração conjunta de alendronato de sódio (ALN) e vitamina D3 (VD) atua na microarquitetura óssea em ratas com osteoporose induzida por glicocorticoide. Métodos O experimento utilizou 32 ratas da linhagem Wistar, com peso médio de 300 a 400g, com 90 dias de vida. A indução da osteoporose consistiu na administração de dexametasona na dose de 7,5 mg/kg de peso corporal, por via intramuscular, 1 vez por semana durante 5 semanas, à exceção dos animais do grupo controle. Os animais foram distribuídos nos seguintes grupos: G1 (grupo controle sem osteoporose), G2 (grupo controle com osteoporose sem tratamento), G3 (grupo com osteoporose tratado com ALN 0,2 mg/kg), G4 (grupo com osteoporose tratado com VD 10.000UI/500μL) e G5 (grupo com osteoporose tratado com ALN þ VD). Os fêmures direitos das ratas foram fixados em formol a 10% tamponado, descalcificados e processados para inclusão em parafina. Os cortes histológicos foram corados com hematoxilina-eosina para análise histomorfométrica. A espessura cortical e a cavidade medular foram medidas em cortes transversais. Resultados Houve diferença estatística (p< 0,05) entre os grupos G3 e G5 em relação ao grupo controle positivo (G2), tanto em relação à medida da espessura cortical quanto em relação ao diâmetro total do osso. Na avaliação da área medular, apenas o grupo G3 se mostrou estatisticamente diferente do grupo G2. Conclusão O tratamento concomitante com ALN diário e VD semanal é eficaz para prevenir a perda óssea induzida por glicocorticoide. No entanto, não houve diferença entre esta terapia testada e o tratamento apenas com o ALN.
Subject(s)
Animals , Rats , Osteoporosis/prevention & control , Vitamin D/therapeutic use , Alendronate/therapeutic use , MenopauseABSTRACT
Objetivo: avaliar a eficácia da utilização da terapia combinada de alendronato de sódio e vitamina D no metabolismo ósseo de mulheres em tratamento de osteoporose pós-menopausa. Métodos: trata-se de uma revisão sistemática, a qual foram pesquisados ensaios clínicos randomizados (ECR) indexados nas bases de dados BVS, ISI Web of Science, PubMed, SciELO, ScienceDirect e Scopus que comparavam a associação de alendronato sódico e vitamina D com a monoterapia de alendronato de sódio. Resultados: um total de seis ECR contemplou os critérios para serem inclusos nesse estudo, compreendendo um total de 4164 participantes e seus respectivos dados. Os estudos avaliaram diferentes domínios do metabolismo ósseo, como níveis séricos de vitamina D, paratormônio, densidade mineral óssea e marcadores de turnover ósseo. A terapia combinada produziu melhora significativa nos marcadores metabólicos ósseos. Conclusão: a terapia combinada de alendronato de sódio com vitamina D promove melhora no metabolismo ósseo de mulheres com osteoporose pós-menopausa.
Aim: to evaluate the effectiveness of using the combined therapy of sodium alendronate and vitamin D on bone metabolism in women undergoing postmenopausal osteoporosis. Methods: this is a systematic review. The studies included were Randomized Controlled Trials (RCT) indexed in the BVS, ISI Web of Science, PubMed, SciELO, ScienceDirect and Scopus Databases which compared the association of sodium alendronate and vitamin D to monotherapy of sodium alendronate. Results: a total of six RCT met the criteria to be included in this study, comprising a total of 4164 participants and their respective data. The studies evaluated different domains of bone metabolism, such as serum levels of vitamin D, parathyroid hormone, bone mineral density and bone turnover markers. Combination therapy produced significant improvement in bone metabolic markers. Conclusion: combined therapy of sodium alendronate with vitamin D promotes improved bone metabolism in women with postmenopausal osteoporosis.
Subject(s)
Humans , Female , Parathyroid Hormone , Vitamin D , Women , Bone and Bones , Bone Density , Osteoporosis, Postmenopausal , AlendronateABSTRACT
RESUMO Objetivo Elucidar se a suplementação com ácido fólico pouco antes da concepção e/ou durante a gestação pode estar realmente atrelado ao desenvolvimento do transtorno do espectro autista (TEA). Metódos Foi realizada uma revisão de literatura em base de dados, nos idiomas português e inglês, durante o período de novembro de 2017 até abril de 2018, com ênfase nas publicações mais recentes. Resultados Do total de 174 artigos, 87 compuseram este trabalho. Pesquisas apontam que o aumento dos casos de TEA se deve ao fato de que mais fatores genéticos estejam implicados na etiopatogênese neural. No entanto, a grande maioria dos artigos ressalta com maior precisão que há mais efeitos benéficos do uso de ácido fólico antes da concepção e durante a gestação na prevenção do TEA, assim como de outras anormalidades relacionadas aos defeitos do tubo neural. Conclusão Quando se analisa o risco-benefício da suplementação com ácido fólico nas doses recomendadas, 0,4 a 0,8 mg/dia, conclui-se que os benefícios sobrepujam os possíveis riscos de desenvolver o TEA.
ABSTRACT Objective Elucidating whether supplementation with folic acid shortly before conception and/or during pregnancy may actually be linked to the development of Autistic Spectrum Disorder (ASD). Methods A literature review was conducted in the Portuguese and English languages during the period from November 2017 to April 2018, with emphasis on the most recent publications. Results Of the total of 174 articles, 87 compose this work. Research indicates that the increase in ASD cases should take into account the fact that more genetic factors are implicated in neural pathogenesis. However, a large majority of articles point out that there are more beneficial effects of using folic acid before application and during pregnancy in the prevention of ASD, as well as other abnormalities related to neural tube defects. Conclusion When analyzing the risk-benefit of folic acid supplementation at the recommended doses, 0.4 to 0.8 mg/day, it is concluded that the benefits outweigh the possible risks of developing ASD.
ABSTRACT
PURPOSE: To assess the histological response of damaged osteochondral tissue in the femoral condyles of rabbits after repairing the wounds with sugar cane biopolymer gel - compared to the control group. METHODS: The study investigated 16 New Zealand rabbits, at 90, 120 and 180 days after surgery. In all the animals, a lesion of 3.2 mm in diameter and 4 mm deep was induced in each right and left femoral condyle. Each animal has provided both knees, divided into medial and lateral condyle, resulting in 64 samples. 32 knees were divided into two groups: Right knee, medial and lateral condyles, filled with biopolymer; Left knee, medial and lateral condyles, unfilled. The anatomical specimens were removed, and subjected to histological techniques and morphometric and statistical analysis. RESULTS: In all the periods of the group under study an inflammatory reaction mediated by giant cells and mononuclear cells was found, while in the control group there was early healing produced by fibroblasts and few mononuclear cells with statistical significance between groups. CONCLUSION: The biopolymer gel caused an inflammatory reaction mediated by giant cells and mononuclear cells while the control group there was cicatrization mediated by fibroblasts.
Subject(s)
Animals , Rabbits , Biopolymers/therapeutic use , Cartilage, Articular/injuries , Femur/injuries , Saccharum/chemistry , Wound Healing/drug effects , Bone Substitutes/therapeutic use , Cartilage, Articular/pathology , Femur/pathology , Fibroblasts/drug effects , Gels/therapeutic use , Giant Cells/drug effects , Reproducibility of Results , Time Factors , Treatment OutcomeABSTRACT
The northeast region of Brazil is endemic for zoonotic visceral leishmaniasis (ZVL). The aim of this study was to determine the prevalence of infection in dogs in Petrolina. Blood samples were collected from dogs (n = 600), and bone-marrow biopsy was performed in animals with positive serological test results that presented clinical signs of ZVL. The serological analyses were performed using an enzyme-linked immunosorbent assay (ELISA) (S7(r)Biogene). Of the 600 dogs tested, 19% (115/600) presented anti- Our data are important because canine infection is an important risk factor for the human disease.
Subject(s)
Animals , Dogs , Female , Male , Antibodies, Protozoan/blood , Dog Diseases/epidemiology , Leishmania infantum/immunology , Leishmaniasis, Visceral/veterinary , Brazil/epidemiology , Dog Diseases/diagnosis , Endemic Diseases , Enzyme-Linked Immunosorbent Assay/veterinary , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/epidemiology , Prevalence , Rural Population , Urban PopulationABSTRACT
We investigated the effect of hydroalcoholic extract the Petiveria alliacea root on fetal and placental development female rats pregnancy. Thirty female rats were mated and divided in groups: I - rats treated with placebo and sacrificed on the 7th day; II - rats treated with hydroalcoholic extract and sacrificed on the 7th day; III - rats treated with placebo and sacrificed on the 14th day; IV - rats treated with hydroalcoholic extract and sacrificed on the 14th day; V - rats treated with placebo for analysis of the offspring; VI - rats treated with hydroalcoholic extract for analysis of the offspring. The extract was administered by gavage in the dosage of 18mg/kg body wt., in 5th day of pregnancy. The implantation sites and placenta were fixed in Bouin and processed for the embedding in paraffin. The offspring were weighed, measured and counted. The hydroalcoholic extract of the root of the P. alliacea causes significant reduction in the number of implantation sites, but do not cause histological alterations in these sites and placenta. No alterations in the number, length and weight have been observed in offspring. Our results suggest that the hydroalcoholic extract from the P. alliacea in the dosage of 18mg/kg body wt., administered to female rats, on the 5th day of pregnancy, only cause a retard in the implantation process.
Se investigaron los efectos de la extracto hidroalcohólico de la raíz Petiveria alliacea sobre el desarrollo fetal y placentario en ratas preñadas. Treinta ratas hembras fueron criadas y divididas en grupos: I- Ratas tratadas con placebo y sacrificado en el día 7; II- Ratas tratadas con el extracto hidroalcohólico y sacrificadas en el día 7; III- ratas tratadas con placebo y sacrificado el día 14; IV- ratas tratadas con el extracto hidroalcohólico y sacrificaron el día 14; V- ratas tratadas con placebo para el análisis de las crías; VI- ratas tratadas con el extracto hidroalcohólico para el análisis de las crías. El extracto se administró por sonda en dosis de 18mg/kg de peso corporal, en el 5to día de preñez. Los sítios de implantación y la placenta se fijaron en Bouin y se procesaron para la inclusión en parafina. Las crías fueron pesadas, medidas y contadas. El extracto hidroalcohólico de la raíz de P. alliacea provocó una reducción significativa en el número de sitios de implantación, pero no causaron alteraciones histológicas en estos sitios y la placenta. No se observaron alteraciones en el número, longitud y peso de las crías. Nuestros resultados sugieren que el extracto hidroalcohólico de P. alliacea en la dosis de 18mg/kg de peso corporal, administrado a ratas hembras en el 5to día de preñez, sólo causó retardo en el proceso de implantación.
Subject(s)
Animals , Female , Pregnancy , Rats , Fetal Development , Plant Extracts/pharmacology , Phytolaccaceae/chemistry , Placenta , Uterus , Ethanol , Plant Extracts/administration & dosage , Rats, WistarABSTRACT
The glucocorticoid dexamethasone has been largely used due to its anti-inflammatory effect. However, several authors report that the excessive exposition to it during pregnancy may cause a retard in the development in several tissues, mainly: liver, lungs and kidneys. But, the majority of the works are done with the application of dexamethasone in the late periods of pregnancy. Because of the lack of researches that evaluate the effects in the beginning of gestation, this paper aimed at evaluating the effect of dexamethasone administered in the initial phase of pregnancy, over the morphology of neonates rat. It was used 10 albino rats (Rattus norvegicus albinus) aged 90 days from the lineage Wistar. The female were coupled and divided in two groups: Group I - rats not submitted to the dexamethasone application (control); Group II - rats submitted to the dexamethasone application in the first 5 days of pregnancy. The results show that the treatment with dexamethasone in a dosage of 0.8mg/Kg during the 5 first days of pregnancy does not produces a weight and height reduction or malformation in the offspring, it does not cause changes in the development of the liver and kidneys of neonate rats, but it leads to a reduction in the denseness of the interalveolar septa causing a higher distension of the alveoli.
El glucocorticoide dexametasona ha sido ampliamente utilizado en virtud de su potencial antiinflamatorio. Sin embargo, varios autores relatan que la exposición excesiva a la dexametasona durante la preñez puede causar el retardo del desarrollo de varios tejidos, principalmente hígado, pulmones y riñones. La mayoría de los trabajos son llevados a cabo con la aplicación de dexametasona en los períodos tardíos de la gestación. El objetivo del trabajo fue evaluar el efecto de la dexametasona, sobre la morfología de ratones neonatos, administrada en la fase inicial de la preñez. Fueron utilizadas 10 ratas Wistar albinas (Rattus norvegicus albinus) con 90 días de edad. Las hembras fueron apareadas y divididas en dos grupos: Grupo I- ratas no sometidas a la dexametasona (grupo control) y Grupo II - ratas sometidas a la aplicación de dexametasona durante los cinco primeros días de preñez. Los resultados mostraron que el tratamiento con dexametasona en dosis de 0,8mg/Kg, a lo largo de los cinco primeros días de la preñez, no produce reducción de peso, longitud o malformación en la prole, tampoco causa alteraciones en el desarrollo del hígado y riñones en los ratones neonatos, pero sí reduce el grosor de los septos interalveolares, causando de esta manera, mayor distensión de los alvéolos.
Subject(s)
Animals , Female , Infant, Newborn , Rats , Pulmonary Alveoli/anatomy & histology , Pulmonary Alveoli , Pulmonary Alveoli/ultrastructure , Dexamethasone/administration & dosage , Dexamethasone/metabolism , Dexamethasone/toxicity , Pregnancy, Animal , Rats, Wistar/anatomy & histology , Rats, Wistar/metabolismABSTRACT
El objetivo del estudio fue obtener información básica del ciclo estral en ratones tratados con dexametasona, en ovarios poliquísticos, inducidos por iluminación continua. Fueron utilizados 30 ratones albinos (Rattus norvegius albinus) del linaje Wistar, con 90 días de edad, divididos en los siguientes grupos: Grupo I ratones mantenidos en ciclo claro/oscuro de 12/12 horas,tras 100 días sometidos a la evaluación de la ciclicidad (control). Grupo II ratones mantenidos bajo iluminación continua, durante 100 días y luego sometidos a la evaluación de la ciclicidad. Grupo III ratones mantenidos bajo iluminación continua, durante 100 días, después tratados con dexametasona durante cinco días y sometidos a la evaluación de la ciclicidad. Los resultados mostraron que tras 100 días de pruebas, los animales del grupo I presentaron una ciclicidad normal, siendo observadas las cuatro fases de éste. En los animales de los grupos II y III se verificó una mayor incidencia de fase de estro, con el porcentaje de 85 por ciento y 76,50 por ciento, respectivamente, caracterizando el estado de estro permanente. Fue observada la fase de diestro en el 15 por ciento, en el grupo II, y 23,5 por ciento en el grupo III, no siendo observadas las fases de proestro y metaestro. Posterior al tratamiento con dexametasona, se verificó una reducción acentuada en la fase de estro en los animales del grupo III, lo que también fue observado en los animales del grupo II , alcanzando un 34,5 por ciento y 20,85, respectivamente. Hubo incluso aumento de la fase de diestro en el grupo II (64,58 por ciento), y grupo III (75 por ciento). Notamos en esos grupos, la presencia de la fase de proestro en el 0,92 por ciento en el grupo II y 4,15 por ciento en el grupo III, no siendo observada la fase de metaestro. El tratamiento con dexametasona durante cinco días, produce más rápidamente una eventual vuelta del ciclo estral en ratones con poliquistosis ovárica.
The study aimed at obtaining basic information about estrous cycle in rats treated with dexamethasone, for polycystic ovaries, induced by constant illumination. It was used 30 female rats (Rattus norvegicus albinus) from the lineage Wistar, with 90 days years old, divided according the following groups: Group I - rats maintained in a light/dark cycle for 12/12 hours, and after 100 days submitted to the cyclicity evaluation (control); Group II - rats maintained under constant illumination during 100 days and after submitted to the cyclicity evaluation; Group III - rats maintained under constant illumination during 100 days and after treated with dexamethasone for five days, and, then, submitted to the cyclicity evaluation. The results showed that after 100 days of experiment, the animals from group I presented a normal cyclicity, being observed the four phases of the cycle. In the animals of groups II and III, it was observed a higher incidence in the estrous phase, with 85% and 76,5% respectively, characterizing the state of permanent estrous. It was observed the phase of diestrous with 15% in group II, and 23,5% in group III, not being observed the phases of proestrous and metaestrous. After treatment with dexamethasone, it was verified a great reduction in the estrous phases in the animals from group III, what was also observed in the animals from group II, reaching numbers of 34,5% and 20,85%, respectively. Yet, there was an increase in the diestrous phase in group II (64,57%), and group III (75%). It has been noticed in these groups the presence of the proestrous phase with 0,92% in group II and 4,15% in group III, not being observed the metaestrous phase. The treatment with dexamethasone during five days produces, more rapidly, a possible retake of the estrous cycle in rats with ovarian polycystic ovaries.